CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing
CellProthera CSO Ibon Garitaonandia will present data from recent Phase I/IIb trial for ProtheraCytes at the conference...
International board features extensive background in cardiology, pharma development, and commercial development
Exciting News from the EIT Health Fast Track Programme!
Great news of December 15th 2024!
CellProthera will carry out technology transfer ahead of autologous CD34+ endothelial progenitor cell clinical trials planned by...
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease...
Speaking at a press conference, CellProthera’s CEO said the company is moving into the final phase of...
Revolutionizing Cardiac Regeneration.
Positive pre-IND meeting with FDA helps position CellProthera for a U.S. and international Phase III trial for...
The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair and...
MULHOUSE, France, and SUNNYVALE, California USA – July 8, 2024 CellProthera, a private company specializing in cell-based...
July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative...
Researchers harvest stem cells from patients who have recently had a heart attack and use them to...
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following...
Positive changes in prognostic biomarkers including infarct size, left ventricular dimensions and NT-proBNP level support the anti-remodeling...
Mulhouse, France, April 23 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases will...
DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future...
Didier HAGUENAUER – CMO – CELLPROTHERA